Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SME3110 (Fluvoxamine) in Pediatric OCD
NCT01933919Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of fluvoxamine in obsessive compulsive disorder (OCD), sponsored by AbbVie Inc.. Started Aug 2013; status: completed.
02
Drugs
fluvoxamine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT01933919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01933919.